ClinicalTrials.gg
WithdrawnNCT03386838Updated Apr 18, 2019

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

A Phase 3 interventional study of Nivolumab and BMS-986205 in Head and Neck Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

How we know · 14 judgments

Why this study was withdrawn
Business objectives have changed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb — 1 open to participants now, 1 under way, none of them phase 3. Head and Neck Neoplasms · Bristol-Myers Squibb.

Enrollment
13th of 13
0 · median 50
Started
2018
with 1 other
Phase 3
2 of 18
none open now
Registered
15th of 18
by date

Among the 18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 3, and was the 15th registered.

Head and Neck Neoplasms

2,716 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 455 Head and Neck Neoplasms studies recruiting now, 347 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first diagnosed.

03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • confirmed squamous cell carcinoma of the head and neck (SCCHN), from any of the following primary sites only: oral cavity, oropharynx, hypopharynx, and larynx.
  • Recurrent or disease that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
  • No prior treatment with systemic anti-cancer therapy for SCCHN, unless protocol specified criteria are met
  • Performance Status of 0-1
  • by CT or MRI per 1.1 criteria

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Recurrent or carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary, squamous cell carcinoma that originated from the skin and salivary gland or paranasal sinus, non-squamous histologies (eg, mucosal melanoma)
  • Participants with untreated are excluded
  • Participants with carcinomatous meningitis
  • Prior active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Nivolumab and BMS-986205

    Nivolumab administered in combination with BMS-986205

    Biological: Nivolumab · Drug: BMS-986205

  • Active comparator
    EXTREME study regimen

    Cetuximab + Cisplatin/Carboplatin + Fluorouracil

    Biological: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: Fluorouracil

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • DrugLinrodostatStudies of LinrodostatLinrodostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered 100mg orally once daily for a maximum of 104 weeks

  • BiologicalCetuximab

    400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason

  • Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)

  • Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)

  • 1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) as determined by Blinded Independent Central Review (BICR) using RECIST 1.1

    Time frame: Approximately 2 years

  2. Overall survival (OS)

    Time frame: Approximately 40 months

  3. Objective response rate (ORR) determined by BICR using RECIST 1.1

    Time frame: Approximately 2 years

Secondary outcomes

  1. Number of adverse events (AE)

    Time frame: Approximately 2 years

  2. Number of serious adverse events (SAE)

    Time frame: Approximately 2 years

  3. Time to meaningful symptomatic deterioration (TTSD)

    Time frame: Approximately 2 years

07

Study locations

1 site
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212-0000, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Apr 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Dec 29, 2017
StartActual
Mar 28, 2018
Primary completionActual
Apr 19, 2018
CompletionActual
Apr 19, 2018
Last update
Apr 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03386838
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Mar 28, 2018
Primary completion
Apr 19, 2018
Completion
Apr 19, 2018
Last update
Apr 18, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linrodostat

Start the discussion